Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Lifestyle Interventions and Supplements for Joint and Arthritis Pain: A Narrative Review.

American journal of lifestyle medicine·2025
Same author

International Analysis of Para Versus Able-Bodied Sport Medical and Executive Governing Boards: Exploring the Impact of Physiatry.

American journal of physical medicine & rehabilitation·2025
Same author

Conventional and non-conventional antigen-binding sites promote the development and function of chronic lymphocytic leukemia stereotyped subset #4 clones.

Frontiers in immunology·2025
Same author

Increasing Access to Physical Activity Opportunities for Patients: A Review.

American journal of lifestyle medicine·2025
Same author

Chronic lymphocytic leukemia often arises by a multiclonal selection process.

Haematologica·2025

Related Experiment Video

Updated: Jul 2, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Alemtuzumab in the up-front setting.

Matthew Kaufman1, Kanti R Rai

  • 1Long Island Jewish Medical Center New Hyde Park, NY, USA.

Therapeutics and Clinical Risk Management
|August 30, 2008
PubMed
Summary

Alemtuzumab effectively treats chronic lymphocytic leukemia (CLL), showing promise as a frontline therapy and in achieving minimal residual disease (MRD) eradication, especially for high-risk patients.

Keywords:
11q deletion17p deletionalemtuzumabchronic lymphocytic leukemiaconsolidationminimal residual disease

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jul 2, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Alemtuzumab is a monoclonal antibody targeting CD52.
  • It is established in refractory chronic lymphocytic leukemia (CLL) treatment.
  • Its role in frontline therapy and MRD eradication is evolving.

Purpose of the Study:

  • To define the evolving role of alemtuzumab in CLL treatment.
  • To assess its efficacy in frontline therapy and high-risk patient populations.
  • To evaluate its potential in achieving minimal residual disease (MRD) negativity.

Main Methods:

  • Review of early trials and the CAM307 trial.
  • Analysis of alemtuzumab's activity in bone marrow and spleen.
  • Evaluation of consolidation trials for MRD eradication.

Main Results:

  • Alemtuzumab demonstrated efficacy as monotherapy in frontline CLL treatment.
  • Improved responses were observed in patients with high-risk cytogenetic abnormalities (e.g., 17p del, 11q del).
  • Consolidation trials showed promising results for MRD eradication.

Conclusions:

  • Alemtuzumab is FDA-approved for frontline CLL therapy.
  • Its potent bone marrow activity suggests a key role in combination therapy for MRD eradication.
  • Further investigation is needed to confirm the benefit of MRD negativity.